Rolapitant, also known as SCH-619734, is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy.
Wang, Baoan. Synthesis method of rolapitan (varubi) for treating cancer chemotherapy-induced nausea and emesis. CN 107383008 (Faming Zhuanli Shenqing (2017))
Tian, Zhenping; Qi, Xianliang; Hu, Xiaoyan; Wen, Dongsheng; Gao, Yonghong; Li, Dianqing; Jiang, Ziwei; Long, Shenjie; Wu, Zhaochun; Fan, Chuanwen. Process for the preparation of NK-1 receptor antagonist (5S,8S)-8-[[[1(R)-(3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and its intermediate. CN 105017251. (Faming Zhuanli Shenqing (2015))
Wu, George G.; Werne, Gerald; Fu, Xiaoyong; Orr, Robert K.; Chen, Frank Xing; Cui, Jian; Sprague, Victoria M.; Zhang, Fucheng; Xie, Ji; Zeng, Liansheng; et al. Process and intermediates for the synthesis of 8-[[1-[3,5-bis-(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one compounds. WO 2010028232. (PCT Int. Appl. (2010))
Mergelsberg, Ingrid; Scherer, Dominik Hermann; Huttenloch, Monika Erika; Tsui, Hon-Chung; Paliwal, Sunil; Shih, Neng-Yang. Process for the preparation of spiro-lactam compound. WO 2008118328. (PCT Int. Appl. (2008))
Paliwal, Sunil; Reichard, Gregory A.; Wang, Cheng; Xiao, Dong; Tsui, Hon-Chung; Shih, Neng-Yang; Arredondo, Juan D.; Wrobleski, Michelle Laci; Palani, Anandan. Preparation of pyrrolidine and piperidine derivatives for therapeutic use as neurokinin 1 (NK1) receptor antagonists. WO 2003051840. (PCT Int. Appl. (2003))
